Rallybio Co. (NASDAQ:RLYB) Receives $10.00 Consensus Target Price from Analysts

Shares of Rallybio Co. (NASDAQ:RLYB – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price […]

Leave a Reply

Your email address will not be published.

Previous post Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $63.83 Average PT from Analysts
Next post Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives $9.83 Consensus Price Target from Analysts